

Interim Condensed Consolidated Financial Statements of

MEDICAL FACILITIES CORPORATION

For the three and nine months ended September 30, 2025

(Unaudited)

(In U.S. dollars)

TABLE OF CONTENTS

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	Page
Interim Condensed Consolidated Balance Sheets	2
Interim Condensed Consolidated Statements of Changes in Equity	3
Interim Condensed Consolidated Statements of Income and Comprehensive Income	4
Interim Condensed Consolidated Statements of Cash Flows	5

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

	Page
1. Reporting entity	6
2. Statement of compliance	6
3. Basis of preparation	6
4. Government stimulus	7
5. Discontinued operations	8
6. Earnings per share	9
7. Normal course issuer bids	11
8. Substantial issuer bid	12
9. Obligation for purchase of common shares	12
10. Net changes in non-cash working capital	12
11. Financial instruments	13
12. Income taxes	14
13. Interest expense, net of interest income	14
14. Related party transactions	15
15. Commitments and contingencies	16
16. Share-based compensation	16
17. Material accounting policies	19

MEDICAL FACILITIES CORPORATION

Interim Condensed Consolidated Balance Sheets
(In thousands of U.S. dollars)

	Note	September 30, 2025 \$ (Unaudited)	December 31, 2024 \$
ASSETS			
Current assets			
Cash and cash equivalents		46,814	108,496
Accounts receivable		40,450	45,468
Supply inventory		6,327	5,805
Prepaid expenses and other receivables		3,138	5,479
Income tax receivable		708	87
Total current assets		97,437	165,335
Non-current assets			
Deferred income tax asset		27	129
Property and equipment		49,122	50,522
Right-of-use assets		25,479	32,482
Goodwill		90,600	90,600
Other intangibles		6,822	7,226
Total non-current assets		172,050	180,959
TOTAL ASSETS		269,487	346,294
LIABILITIES AND EQUITY			
Current liabilities			
Dividends payable		1,186	1,441
Accounts payable		15,031	16,940
Accrued liabilities		19,159	20,809
Income tax payable		-	13,766
Obligation for purchase of common shares	9	6,908	16,694
Current portion of long-term debt		4,894	10,390
Current portion of lease liabilities		7,225	8,909
Total current liabilities		54,403	88,949
Non-current liabilities			
Long-term debt		27,662	23,833
Lease liabilities		25,313	30,805
Deferred income tax liability		17,055	15,952
Exchangeable interest liability		34,967	39,303
Total non-current liabilities		104,997	109,893
Total liabilities		159,400	198,842
Equity			
Share capital		268,200	316,927
Contributed surplus		470	470
Accumulated deficit		(182,543)	(195,378)
Equity attributable to owners of the Corporation		86,127	122,019
Non-controlling interest		23,960	25,433
Total equity		110,087	147,452
TOTAL LIABILITIES AND EQUITY		269,487	346,294

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

MEDICAL FACILITIES CORPORATION

Interim Condensed Consolidated Statements of Changes in Equity

(In thousands of U.S. dollars)

(Unaudited)

	Note	Attributable to Owners of the Corporation			Non-controlling Interest	Total Equity
		Share Capital	Contributed Surplus	Accumulated Deficit		
		\$	\$	\$	\$	\$
2025						
Balance at January 1, 2025		316,927	470	(195,378)	25,433	147,452
Net income and comprehensive income for the period		-	-	16,486	15,062	31,548
Dividends to owners of the Corporation		-	-	(3,651)	-	(3,651)
Distributions to non-controlling interest		-	-	-	(16,535)	(16,535)
Purchase of common shares under a normal course issuer bid	7	(14,764)	-	-	-	(14,764)
Purchase of common shares under a substantial issuer bid	8	(43,749)	-	-	-	(43,749)
Change in obligation for purchase of common shares	9	9,786	-	-	-	9,786
Balance at September 30, 2025		268,200	470	(182,543)	23,960	110,087
2024						
Balance at January 1, 2024		348,099	716	(262,827)	32,315	118,303
Net income and comprehensive income for the period		-	-	8,646	23,878	32,524
Stock options expense	16.1	-	26	-	-	26
Dividends to owners of the Corporation		-	-	(4,600)	-	(4,600)
Distributions to non-controlling interest		-	-	-	(21,470)	(21,470)
Purchase of common shares under a normal course issuer bid	7	(11,343)	-	-	-	(11,343)
Change in obligation for purchase of common shares	9	(1,414)	-	-	-	(1,414)
Balance at September 30, 2024		335,342	742	(258,781)	34,723	112,026

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

MEDICAL FACILITIES CORPORATION

Interim Condensed Consolidated Statements of Income and Comprehensive Income
(In thousands of U.S. dollars, except per share amounts)
(Unaudited)

	Note	Three Months Ended September 30,		Nine Months Ended September 30,	
		2025 \$	2024 ⁽¹⁾ \$	2025 \$	2024 ⁽¹⁾ \$
Revenue and other income					
Facility service revenue		82,561	76,821	244,832	240,452
Government stimulus income	4	-	11,957	-	11,957
		82,561	88,778	244,832	252,409
Operating expenses					
Salaries and benefits		23,566	22,182	69,033	66,111
Drugs and supplies		28,377	25,679	82,852	81,298
General and administrative expenses		14,558	15,315	43,625	45,474
Depreciation of property and equipment		1,403	1,670	4,483	5,027
Depreciation of right-of-use assets		2,356	2,363	7,291	7,025
Amortization of other intangibles		136	136	404	405
		70,396	67,345	207,688	205,340
Income from operations		12,165	21,433	37,144	47,069
Finance costs (income)					
Change in value of exchangeable interest liability		(5,625)	4,935	(4,336)	18,680
Interest expense on exchangeable interest liability		1,265	1,926	3,810	5,681
Interest expense, net of interest income	13	521	919	1,032	3,148
Loss on foreign currency		18	14	177	68
		(3,821)	7,794	683	27,577
Income before income taxes		15,986	13,639	36,461	19,492
Income tax expense (recovery)	12	3,057	(347)	4,913	(1,272)
Net income for the period from continuing operations		12,929	13,986	31,548	20,764
Discontinued operations					
Net income for the period from discontinued operations, net of tax	5.1	-	3,433	-	11,760
Net income and comprehensive income for the period		12,929	17,419	31,548	32,524
Attributable to:					
Owners of the Corporation		8,127	7,246	16,486	8,646
Non-controlling interest		4,802	10,173	15,062	23,878
		12,929	17,419	31,548	32,524

Earnings per share attributable to owners of the Corporation

From continuing and discontinued operations

Basic	6	\$ 0.44	\$ 0.30	\$ 0.83	\$ 0.36
Fully diluted	6	\$ 0.23	\$ 0.30	\$ 0.72	\$ 0.36

From continuing operations

Basic	6	\$ 0.44	\$ 0.23	\$ 0.83	\$ 0.13
Fully diluted	6	\$ 0.23	\$ 0.23	\$ 0.72	\$ 0.13

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

⁽¹⁾ The comparative results for the three and nine months ended September 30, 2024 include the results of continuing operations and discontinued operations. In accordance with IFRS 5, Non-current Assets Held for Sale and Discontinued Operations, the results of discontinued operations for the prior period are presented separately in the current period's interim condensed consolidated statements of income and comprehensive income to provide a clear comparison.

MEDICAL FACILITIES CORPORATION

Interim Condensed Consolidated Statements of Cash Flows

(In thousands of U.S. dollars)

(Unaudited)

	Note	Nine Months Ended September 30,	
		2025	2024
		\$	\$
Cash flows from operating activities			
Net income for the period		31,548	32,524
Adjustments for:			
Depreciation of property and equipment		4,483	6,680
Depreciation of right-of-use assets		7,291	7,559
Amortization of other intangibles		404	405
Change in value of exchangeable interest liability		(4,336)	18,680
Interest expense on exchangeable interest liability		3,810	5,681
Interest expense, net of interest income		1,032	3,621
Loss on foreign currency		177	68
Income tax expense		4,913	340
Stock options expense	16.1	-	26
Other non-cash (gain) loss		(62)	6
		49,260	75,590
Net changes in non-cash operating working capital	10	3,278	(1,755)
		52,538	73,835
Interest paid, net of received		(3,311)	(7,546)
Income and withholding taxes paid		(18,095)	(4,973)
Net cash provided by operating activities		31,132	61,316
Cash flows from investing activities			
Purchase of property and equipment		(3,083)	(5,920)
Net cash used in investing activities		(3,083)	(5,920)
Cash flows from financing activities			
Net issuance of notes payable and repayments of revolving credit facilities		1,028	(10,362)
Repayments of notes payable by the Facilities		(2,695)	(3,989)
Payment of lease liabilities		(8,933)	(9,069)
Distributions to non-controlling interest		(16,535)	(21,470)
Dividends paid		(3,906)	(4,540)
Purchase of common shares under normal course issuer bids	7	(14,764)	(11,343)
Purchase of common shares under a substantial issuer bid	8	(43,749)	-
Net cash used in financing activities		(89,554)	(60,773)
Decrease in cash and cash equivalents		(61,505)	(5,377)
Effect of exchange rate fluctuations on cash balances held		(177)	(68)
Cash and cash equivalents, beginning of the period		108,496	24,113
Cash and cash equivalents, end of the period		46,814	18,668

The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

1. REPORTING ENTITY

Medical Facilities Corporation (the “Corporation”) is a British Columbia corporation. The address of the Corporation’s head office is 4576 Yonge Street, Suite 701, Toronto, Ontario, Canada. The common shares of the Corporation are listed on the Toronto Stock Exchange under the ticker symbol “DR”.

The Corporation’s operations are based in the United States. Through its wholly-owned subsidiaries, the Corporation owns controlling interests in three specialty surgical hospitals and one ambulatory surgery center (“ASC”) (collectively the “Facilities”).

The Corporation’s ownership interest in, and the location of, its operating subsidiaries are as follows:

Subsidiary	Location	Ownership Interest September 30,	
		2025	2024
Arkansas Surgical Hospital, LLC (“ASH”)	North Little Rock, Arkansas	51.0%	51.0%
Oklahoma Spine Hospital, LLC (“OSH”)	Oklahoma City, Oklahoma	64.0%	64.0%
Sioux Falls Specialty Hospital, LLP (“SFSH”)	Sioux Falls, South Dakota	51.0%	51.0%
The Surgery Center of Newport Coast (“SCNC”)	Newport Beach, California	51.0%	51.0%
Black Hills Surgical Hospital, LLP (“BHSH”) ⁽¹⁾	Rapid City, South Dakota	-	54.2%

⁽¹⁾ The Corporation completed the sale of BHSH during the year ended December 31, 2024.

2. STATEMENT OF COMPLIANCE

These unaudited interim condensed consolidated financial statements (“consolidated financial statements”) have been prepared in accordance with International Accounting Standard IAS 34, *Interim Financial Reporting* as issued by the International Accounting Standards Board using the accounting policies as described in the audited consolidated financial statements for the year ended December 31, 2024 (“annual financial statements”).

These consolidated financial statements were approved for issue by the Corporation’s Board of Directors on November 5, 2025.

3. BASIS OF PREPARATION

These consolidated financial statements do not contain all of the disclosures that are required in annual financial statements prepared under International Financial Reporting Standards (“IFRS Accounting Standards”) and should be read in conjunction with the Corporation’s annual financial statements, which include information necessary or useful to understand the Corporation’s business and financial statement presentation.

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

3. BASIS OF PREPARATION (Continued)

Income from operations for the interim period is not necessarily indicative of the results for the full year. Facility service revenue and certain directly related expenses are subject to seasonal fluctuations due to the timing of case scheduling, which can be impacted by the vacation schedules of surgeons, as well as the extent to which patients have remaining deductibles on their insurance coverage, based on the time of year. Occupancy related expenses, certain operating expenses, depreciation and amortization, and interest expense remain relatively steady throughout the year.

The Corporation's consolidated financial statements are reported in U.S. dollars which is its functional and presentation currency. All financial information presented in U.S. dollars has been rounded to the nearest thousand, unless otherwise indicated.

4. GOVERNMENT STIMULUS

The *Coronavirus Aid, Relief, and Economic Security (CARES) Act* (the "CARES Act") was signed into law on March 27, 2020 in response to COVID-19. The CARES Act included provisions for financial assistance to healthcare providers via, among other provisions, the Paycheck Protection Program ("PPP").

During the three months ended September 30, 2024, the U.S. Small Business Administration concluded the Post Payment Loan Reviews on all of the Facilities' outstanding PPP loans of \$11,957, closing the reviews with no findings and confirming full forgiveness. As a result, the respective Facilities recorded government stimulus income of \$11,957 in the interim condensed consolidated statement of income and comprehensive income for the three and nine months ended September 30, 2024, and the related liability under government stimulus funds repayable in the interim condensed consolidated balance sheet was reversed.

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

5. DISCONTINUED OPERATIONS

On November 15, 2024, BHSH was sold to Sanford Health for cash proceeds of \$96,136 for the Corporation's 54.2% ownership share, subject to customary adjustments.

5.1 Results of discontinued operations

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
	\$	\$	\$	\$
Revenue and other income				
Facility service revenue	-	26,752	-	78,554
	-	26,752	-	78,554
Operating expenses				
Salaries and benefits	-	11,882	-	34,300
Drugs and supplies	-	6,708	-	19,912
General and administrative expenses	-	3,350	-	8,310
Depreciation of property and equipment	-	518	-	1,653
Depreciation of right-of-use assets	-	192	-	534
	-	22,650	-	64,709
Income from operations	-	4,102	-	13,845
Finance costs				
Interest expense, net of interest income	-	181	-	473
	-	181	-	473
Income before income taxes	-	3,921	-	13,372
Income tax expense	-	488	-	1,612
Net income for the period from discontinued operations, net of tax	-	3,433	-	11,760

5.2 Cash flows from discontinued operations

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
	\$	\$	\$	\$
Net cash provided by operating activities	-	2,411	-	7,369
Net cash used in investing activities	-	(146)	-	(2,360)
Net cash used in financing activities	-	(3,545)	-	(6,787)
Net cash flow for the period	-	(1,280)	-	(1,778)

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

6. EARNINGS PER SHARE

Basic earnings per share attributable to owners of the Corporation are calculated as follows:

Three Months Ended September 30,						
	2025			2024		
	Continuing Operations	Discontinued Operations	Total	Continuing Operations	Discontinued Operations	Total
Net income for the period attributable to owners of the Corporation	\$ 8,127	-	8,127	5,608	1,638	7,246
Divided by weighted average number of common shares outstanding for the period	18,595,164	-	18,595,164	23,769,680	23,769,680	23,769,680
Basic earnings per share	\$ 0.44	-	0.44	0.23	0.07	0.30

Nine Months Ended September 30,						
	2025			2024		
	Continuing Operations	Discontinued Operations	Total	Continuing Operations	Discontinued Operations	Total
Net income for the period attributable to owners of the Corporation	\$ 16,486	-	16,486	3,008	5,638	8,646
Divided by weighted average number of common shares outstanding for the period	19,954,362	-	19,954,362	24,216,587	24,216,587	24,216,587
Basic earnings per share	\$ 0.83	-	0.83	0.13	0.23	0.36

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

6. EARNINGS PER SHARE (Continued)

Fully diluted earnings per share attributable to owners of the Corporation are calculated as follows:

Three Months Ended September 30,						
	2025			2024		
	Continuing Operations	Discontinued Operations	Total	Continuing Operations	Discontinued Operations	Total
Net income for the period attributable to owners of the Corporation	\$ 8,127	-	8,127	5,608	1,638	7,246
Change in value of exchangeable interest liability (tax effected)	(4,275)	-	(4,275)	-	-	-
Interest expense on exchangeable interest liability	1,265	-	1,265	-	-	-
Modified net income for the period attributable to owners of the Corporation	\$ 5,117	-	5,117	5,608	1,638	7,246
Weighted average number of common shares:						
Outstanding for the period	18,595,164	-	18,595,164	23,769,680	23,769,680	23,769,680
Deemed to be issued on the exchange of the outstanding exchangeable interest liability	3,469,554	-	3,469,554	-	-	-
Dilutive weighted average number of common shares ⁽¹⁾	22,064,718	-	22,064,718	23,769,680	23,769,680	23,769,680
Fully diluted earnings per share	\$ 0.23	-	0.23	0.23	0.07	0.30

⁽¹⁾ For the three months ended September 30, 2024, the impact of exchangeable interest liability was excluded from the dilutive weighted average number of common shares calculation because it was anti-dilutive based on the share price prevailing at September 30, 2024.

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

6. EARNINGS PER SHARE (Continued)

	Nine Months Ended September 30,					
	2025			2024		
	Continuing Operations	Discontinued Operations	Total	Continuing Operations	Discontinued Operations	Total
Net income for the period attributable to owners of the Corporation	\$ 16,486	-	16,486	3,008	5,638	8,646
Change in value of exchangeable interest liability (tax effected)	(3,295)	-	(3,295)	-	-	-
Interest expense on exchangeable interest liability	3,810	-	3,810	-	-	-
Modified net income for the period attributable to owners of the Corporation	\$ 17,001	-	17,001	3,008	5,638	8,646
Weighted average number of common shares:						
Outstanding for the period	19,954,362	-	19,954,362	24,216,587	24,216,587	24,216,587
Deemed to be issued on the exchange of the outstanding exchangeable interest liability	3,532,185	-	3,532,185	-	-	-
Dilutive weighted average number of common shares ⁽¹⁾	23,486,547	-	23,486,547	24,216,587	24,216,587	24,216,587
Fully diluted earnings per share	\$ 0.72	-	0.72	0.13	0.23	0.36

⁽¹⁾ For the nine months ended September 30, 2024, the impact of exchangeable interest liability was excluded from the dilutive weighted average number of common shares calculation because it was anti-dilutive based on the share price prevailing at September 30, 2024.

7. NORMAL COURSE ISSUER BIDS

The Corporation has a normal course issuer bid for up to 2,339,066 of its common shares in effect from December 1, 2024 to November 30, 2025. During the nine months ended September 30, 2025, the Corporation purchased 1,305,900 of its common shares for a total consideration of \$14,764 from the open market under this normal course issuer bid. During the nine months ended September 30, 2024, the Corporation purchased 1,230,600 of its common shares for a total consideration of \$11,343 from the open market under a previous normal course issuer bid.

The purchases under the normal course issuer bids are recorded in share capital and include applicable buyback taxes. All common shares acquired under the normal course issuer bids were cancelled.

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

8. SUBSTANTIAL ISSUER BID

On March 11, 2025, the Corporation completed a substantial issuer bid, by way of a modified Dutch auction, to purchase, for cancellation, the common shares of the Corporation (the "Offer"). The Corporation purchased and cancelled 3,374,313 of its common shares at a price of C\$18.00 per common share under the Offer, representing an aggregate purchase price of \$43,145, including applicable buyback taxes, or approximately 14.7% of the Corporation's issued and outstanding common shares before giving effect to the Offer. The Corporation incurred transaction costs related to the Offer of \$604 which have been recorded against share capital for the nine months ended September 30, 2025.

9. OBLIGATION FOR PURCHASE OF COMMON SHARES

The Corporation entered into an automatic share purchase plan with a broker that allows the purchase of common shares for cancellation under the normal course issuer bid, including block purchases, in accordance with certain prearranged trading parameters, at any time during predetermined trading blackout periods. An obligation for purchase of common shares of \$6,908 was recognized under the automatic share purchase plan as of September 30, 2025 (December 31, 2024: \$16,694), including applicable buyback taxes.

Subsequent to the period end, the Corporation purchased 190,600 of its common shares for a total consideration of \$1,958 under the automatic share purchase plan, through October 31, 2025.

10. NET CHANGES IN NON-CASH WORKING CAPITAL

The net changes in non-cash working capital included in the interim condensed consolidated statements of cash flows consist of the following:

	Nine Months Ended September 30,	
	2025	2024
	\$	\$
Accounts receivable	5,018	11,439
Supply inventory	(522)	(667)
Prepaid expenses and other receivables	2,341	2,009
Accounts payable	(1,909)	(4,238)
Accrued liabilities	(1,650)	1,659
Government stimulus funds repayable	-	(11,957)
Net changes in non-cash working capital	3,278	(1,755)

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements
(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)
For the three and nine months ended September 30, 2025
(Unaudited)

11. FINANCIAL INSTRUMENTS

11.1 Fair values and classification of financial instruments

The fair value of exchangeable interest liability is determined based on the closing trading price of common shares at each reporting date. The fair values of long-term debt approximate their carrying values as the interest rates are similar to prevailing market rates. The fair values of all other financial instruments of the Corporation approximate their carrying values due to the short-term nature of these instruments.

The following table presents the carrying values and classification of the Corporation's financial instruments as of September 30, 2025 and December 31, 2024:

	September 30, 2025 \$	December 31, 2024 \$
Financial assets		
Amortized cost		
Cash and cash equivalents	46,814	108,496
Accounts receivable	40,450	45,468
Financial liabilities		
Fair value through profit or loss		
Exchangeable interest liability	34,967	39,303
Amortized cost		
Dividends payable	1,186	1,441
Accounts payable	15,031	16,940
Accrued liabilities	19,159	20,809
Obligation for purchase of common shares	6,908	16,694
Long-term debt	32,556	34,223

The following tables represent the fair value hierarchy of the Corporation's financial instruments that were recognized at amortized cost or fair value through profit or loss as of September 30, 2025 and December 31, 2024. They do not include fair value information for financial instruments which are short-term in nature.

	September 30, 2025			
	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
Financial liabilities				
Exchangeable interest liability	-	34,967	-	34,967
Long-term debt	-	32,556	-	32,556
Total	-	67,523	-	67,523

	December 31, 2024			
	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
Financial liabilities				
Exchangeable interest liability	-	39,303	-	39,303
Long-term debt	-	34,223	-	34,223
Total	-	73,526	-	73,526

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

11. FINANCIAL INSTRUMENTS (Continued)

11.2 Measurement of fair values

The following are the valuation techniques used in measuring Level 2 fair values:

Financial Instrument	Valuation Technique
Exchangeable interest liability	<i>Market comparison technique:</i> The number of the Corporation's common shares to issue is based on the contractual agreements with the holders of non-controlling interest that have exchange agreements with the Corporation and take into account the distributions to the non-controlling interest over the prior twelve months. The liability is valued based on the market price of the Corporation's common shares converted to the reporting currency as of the reporting date.
Long-term debt	<i>Market comparison technique:</i> Interest rates are based on the lending agreements with various banks and creditors of long-term debt, and they are Prime or Secured Overnight Financing Rate ("SOFR") rates adjusted for the Facilities' risk rating, secured assets and other terms of agreements. The liability is valued based on debt principals and interest payments discounted to present value.

12. INCOME TAXES

The U.S. tax return for the Corporation is prepared on a consolidated basis for U.S. entities and includes balances and amounts attributable to these entities.

The Canadian income tax return for the Corporation is prepared on a stand-alone basis and includes non-consolidated balances attributable to the Canadian entity only.

Income taxes from continuing operations reported in these consolidated financial statements are as follows:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025 \$	2024 \$	2025 \$	2024 \$
Provision for income taxes				
Current	1,610	787	3,708	2,448
Deferred	1,447	(1,134)	1,205	(3,720)
Income tax expense (recovery) from continuing operations	3,057	(347)	4,913	(1,272)

13. INTEREST EXPENSE, NET OF INTEREST INCOME

Interest expense, net of interest income, from continuing operations included in the interim condensed consolidated statements of income and comprehensive income consists of the following:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025 \$	2024 \$	2025 \$	2024 \$
Interest expense at the Facility level	438	355	1,276	1,277
Interest expense at the corporate level	-	101	3	453
Interest expense on lease liabilities	478	540	1,531	1,673
Corporate credit facility stand-by fees	42	67	152	195
Interest income at the Facility level	(83)	(76)	(205)	(192)
Interest income at the corporate level	(354)	(68)	(1,725)	(258)
Interest expense, net of interest income, from continuing operations	521	919	1,032	3,148

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

14. RELATED PARTY TRANSACTIONS

Certain Facilities routinely enter into transactions with related parties for provision of services relating to the use of facility space and equipment. These parties are considered related as the Facilities have significant influence over these parties. Such transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.

Certain of the physicians, who indirectly own the non-controlling interest in each of the Facilities, routinely provide professional services directly to patients utilizing the services of the Facilities and reimburse the Facilities for the space and staff utilized. Also, certain of the physicians serve on the boards of management of the Facilities, and three such individuals perform the duties of Medical Director at their respective Facilities and are compensated in recognition of their contribution to the Facilities. Also, Dr. R. Blake Curd, a physician with a non-controlling interest in SFSH, is its Chief Executive Officer and the Chief Medical Officer of the Corporation.

SFSH has a 50% ownership share in an accountable care organization (“ACO”) through a wholly-owned subsidiary that also provides management services to the ACO. The ACO was approved for participation in the Medicare Shared Savings Program, which is an incentive program established under the provisions of the Patient Protection and Affordable Care Act. As one of the initiatives of the ACO, SFSH entered into an agreement with Great Plains Surgical, LLC (“Great Plains”), an entity controlled by certain indirect non-controlling owners of SFSH, for the provision of management services in relation to the orthopedic service line at SFSH to improve the quality of services provided and realize savings on implants and other supplies used in that service line. In addition to the payment of fees for providing management of the orthopedic service line, Great Plains is entitled to receive performance payments for realized cost savings and the attainment of quality levels.

The following is a summary of transactions at each Facility with their respective related parties during the three and nine months ended September 30, 2025 and 2024:

Subsidiary	Nature of services or goods received	Three Months Ended September 30,		Nine Months Ended September 30,	
		2025 \$	2024 \$	2025 \$	2024 \$
ASH	Lease of hospital building and office space, and physician clinic services.	958	860	2,922	2,812
OSH	Lease of hospital building and office space.	657	657	1,970	1,970
SFSH	Provision of management services in relation to orthopedic service line and ACO, anesthesia services, billing and coding services, physical and occupational therapy services, lithotripter services, facility and related equipment, and lease of urgent care building.	3,156	3,163	9,639	9,600
Total		4,771	4,680	14,531	14,382

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

15. COMMITMENTS AND CONTINGENCIES

15.1 Commitments

In the normal course of operations, the Facilities lease certain equipment under non-cancellable long-term leases and enter into various commitments with third parties. In addition, certain Facilities lease their facility space from related and non-related parties.

15.2 Contingencies

In the normal course of business, the Facilities are, from time to time, subject to allegations that may result in litigation. Certain allegations may not be covered by the Facilities' commercial and liability insurance. The Facilities evaluate such allegations by conducting investigations to determine the validity of each potential claim. Based on the advice of legal counsel, management records an estimate of the amount of the ultimate expected loss for each of these matters. Events could occur that would cause the estimate of the ultimate loss to differ materially from the amounts recorded.

16. SHARE-BASED COMPENSATION

16.1 Stock options

The following table summarizes the number of outstanding stock options as of September 30, 2025:

Optionee	Number of Options Held	Number of Options Vested	Exercise Price	Grant Date
Former Chief Executive Officer	223,562	223,562	C\$17.24	May 1, 2016
Former Chief Financial Officer	221,344	221,344	C\$17.98	November 21, 2016
Total number of outstanding options	444,906	444,906		

Outstanding options (the "Options") vest after five years of employment. The Options must be exercised by the tenth anniversary of the respective grant dates, subject to blackout exceptions. As of September 30, 2025, all of the Options are vested.

The movement in the number of outstanding stock options for the nine months ended September 30, 2025 and 2024 was as follows:

Number of outstanding options	2025	2024
Balance at January 1	444,906	744,906
Options exercised during the period	-	-
Options forfeited during the period	-	-
Balance at September 30	444,906	744,906

During the nine months ended September 30, 2025, the Corporation recognized no expense (September 30, 2024: \$26) relating to the Options in salaries and benefits expense.

The grant date fair values of the Options were measured based on the Black-Scholes model. Expected volatility is estimated by considering historic average share price volatility.

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements
(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)
For the three and nine months ended September 30, 2025
(Unaudited)

16. SHARE-BASED COMPENSATION (Continued)

16.2 Deferred share units

Compensation for directors includes a deferred share unit (“DSU”) component, for which grants based on the value of the Corporation’s common shares were made quarterly until the end of the second quarter of 2024, when they were replaced by a restricted share unit (“RSU”) component, after which no additional DSUs are to be issued. The outstanding DSUs vested immediately upon issue, continue to accrue dividends, and can only be redeemed when a participant ceases to serve as a director of the Corporation. The participants’ entitlement in respect of the DSUs then held will be settled in cash based on a formula tied to the value of the Corporation’s common shares at the time of redemption.

During the nine months ended September 30, 2025, 321,787 DSUs were settled in cash for \$3,570, paid out to three directors, Mr. Yanick Blanchard, Ms. Erin Enright and Dr. Reza Shahim (collectively the “Outgoing Directors”), who resigned from the Corporation’s Board of Directors in March 2025. For the nine months ended September 30, 2025, director compensation included no DSU grants (September 30, 2024: \$300), while the change in market value of outstanding DSUs for the same period was an expense of \$84 (September 30, 2024: \$1,355). As of September 30, 2025, accrued liabilities in the interim condensed consolidated balance sheet included a liability for DSUs of \$709 (December 31, 2024: \$4,199).

The following table summarizes changes in the number of DSUs for the nine months ended September 30:

	2025	2024
Opening balance of DSUs at January 1	386,960	351,882
DSUs granted on director fees	-	33,701
DSUs granted on dividend reinvestment	2,991	8,638
DSUs paid out	(321,787)	-
Total number of DSUs at September 30	68,164	394,221

16.3 Performance share unit plan

Until 2024, annual grants of share units (“SUs”) in the form of deferred share units (“Executive DSUs”) were awarded under the Corporation’s Amended Performance Share Unit Plan (“Amended PSU Plan”) but were then replaced by RSUs, after which no additional SU grants are to be made. Awards under the Amended PSU Plan vest three years following their grant date and are subject to achievement of performance objectives set at the time of the grant. The Executive DSUs participate in the Corporation’s quarterly dividend and are settled in cash upon the Amended PSU Plan participants’ departure from the Corporation.

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

16. SHARE-BASED COMPENSATION (Continued)

16.3.1 Share units

SU grants were made annually, each March 31st, from 2020 to 2024, with a final grant on March 28, 2024 for 81,106 Executive DSUs. The value of the expense and liability associated with the outstanding SUs is determined based on the Corporation's share price at the end of each reporting period. For the nine months ended September 30, 2025, operating expenses included an SU expense of \$348 (September 30, 2024: \$934). As of September 30, 2025, accrued liabilities in the interim condensed consolidated balance sheet included a liability for SUs of \$2,661 (December 31, 2024: \$2,313).

The following table summarizes changes in the number of SUs for the nine months ended September 30:

	2025	2024
Opening balance of SUs at January 1	290,472	201,533
SUs granted	-	81,106
SUs granted on dividend reinvestment	5,022	5,981
Total number of SUs at September 30	295,494	288,620

16.4 Restricted share units

The RSUs, granted at the discretion of the Corporation's Board of Directors, are settled in cash. RSU grants were made to directors on December 1, 2024 for 28,199 RSUs, which accrued dividends thereon of 233 RSUs. From this, \$177 was paid out in lieu of 16,108 RSUs to the Outgoing Directors in March 2025. The remaining 12,324 RSUs vested and were settled for \$136 on May 7, 2025.

On June 26, 2025, 30,473 RSUs which vest over one year were granted to directors, and 75,995 RSUs which vest over three years were granted to executives and other employees of the Corporation. These RSUs were awarded under the Corporation's Amended and Restated RSU Plan.

The value of the expense and liability associated with the RSUs is determined based on the Corporation's share price at the end of each reporting period. For the nine months ended September 30, 2025, operating expenses included an RSU expense of \$367 (September 30, 2024: \$nil). As of September 30, 2025, accrued liabilities in the interim condensed consolidated balance sheet included a liability for RSUs of \$233 (December 31, 2024: \$180).

The following table summarizes changes in the number of RSUs for the nine months ended September 30:

	2025	2024
Opening balance of RSUs at January 1	28,199	-
RSUs granted on dividend reinvestment	233	-
RSUs vested and settled	(12,324)	-
RSUs paid out	(16,108)	-
RSUs granted	106,468	-
Total number of RSUs at September 30	106,468	-

MEDICAL FACILITIES CORPORATION

Notes to the Interim Condensed Consolidated Financial Statements

(In thousands of U.S. dollars, except per share amounts and where otherwise indicated)

For the three and nine months ended September 30, 2025

(Unaudited)

17. MATERIAL ACCOUNTING POLICIES

The accounting policies set out in Note 21 to the annual financial statements have been applied consistently to all periods presented in these consolidated financial statements and have been applied consistently by the Facilities.

17.1 New and revised IFRS Accounting Standards not yet adopted

The new and revised IFRS Accounting Standards not yet adopted, as detailed in Note 21.24 to the annual financial statements, also apply to these consolidated financial statements. The Corporation continues to assess the impact of the adoption of these new and revised IFRS Accounting Standards on the consolidated financial statements in future periods. There are no other new and revised IFRS Accounting Standards that have been issued but not yet adopted that would be expected to have a material impact on the Corporation.